Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Prime Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors

NCT05315167 is registered in ClinicalTrials.gov with Zhuhai Yufan Biotechnologies Co., Ltd as lead sponsor.

NCT NCT05315167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05315167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Prime Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
Lead sponsor
Zhuhai Yufan Biotechnologies Co., Ltd
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 30, 2022
Completion date
November 15, 2027
Enrollment
267 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancies, advanced solid tumor